Cagrilintide vs Melanotan II
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Melanotan II
Melanotan II is a synthetic peptide analog of α-MSH with broader receptor activity than Melanotan I. It produces tanning effects and has notable effects on sexual function and appetite suppression.
Full details →Side-by-Side Comparison
| Aspect | Cagrilintide | Melanotan II |
|---|---|---|
| Dose Range | 300 mcg–4.5 mg | 250 mcg–1 mg |
| Frequency | Less than daily | 1x daily |
| Cycle Length | 26–68 weeks | 1–2 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. | Non-selective melanocortin receptor agonist affecting MC1R (tanning), MC3R and MC4R (sexual function and appetite). This broader activity explains its multiple effects beyond tanning. |
| Typical Dosage | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. | Typical protocols: 0.25-0.5mg daily during loading phase for 1-2 weeks, then 0.5-1mg before UV exposure for maintenance. Start low to assess tolerance. |
| Administration | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. | Subcutaneous injection. Usually combined with UV exposure for tanning effects. Nasal spray formulations exist but have lower bioavailability. |
| Side Effects | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. | Nausea (common initially), facial flushing, spontaneous erections, increased libido, appetite suppression, and mole darkening. |
| Best For |
What They Have in Common
Cagrilintide, Melanotan II are both commonly used for:
Key Differences
Unique to Melanotan II:
Which Has Stronger Evidence?
- Fat Loss: Cagrilintide has stronger research support.
| Goal | Cagrilintide | Melanotan II |
|---|---|---|
| Fat Loss | high | low |
Key Studies
Cagrilintide
- Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
The lancet. Diabetes & endocrinology, 2026
- A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.
Nature metabolism, 2026
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
The New England journal of medicine, 2025
Melanotan II
- Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?
International journal of oral and maxillofacial surgery, 2025
- Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.
Dermatology (Basel, Switzerland), 2021
- Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice.
Experimental physiology, 2021
Ready to Learn More?
Looking for trusted sources?